Skip to main content
Premium Trial:

Request an Annual Quote

George Mason to Combine Proteomics and Biodefense Chops to Study Infectious Diseases

NEW YORK (GenomeWeb News) — George Mason University will combine the "expertise" from two of its research centers to use proteomics and molecular biology along with nanotechnology to hunt for blood-borne markers of infectious disease, the University said yesterday.
Using funding from the US Department of Energy, the school plans to combine expertise from its Center for Applied Proteomics and Molecular Medicine with its National Center for Biodefense and Infectious Diseases to create a Biomedical Research laboratory that GMU said will open in 2009.
NCBID Executive Director Charles Bailey said the collaboration “illustrates how proteomic technologies combined with unique nanotechnology methodology can be used to better understand, diagnose, and treat infectious diseases.”
Bailey said the program initially aims to focus on the bacteria that causes anthrax and tularemia, and hopes to find protein biomarkers that could identify disease onset before a patient becomes symptomatic. The researchers will specifically compare pre-symptomatic and post-symptomatic biomarkers found in the blood.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.